Exp Neurobiol 2014; 23(3): 224-230
Published online September 30, 2014
© The Korean Society for Brain and Neural Sciences
Pravin Popatrao Kale1,2, Veeranjaneyulu Addepalli1*, Amrita Sarkar1, Sonam Patel1 and Jay Savai1
Department of Pharmacology, 1SPP SPTM, NMIMS University, 2Dr. Bhanuben Nanavati College of Pharmacy, Mumbai 400-056, India
Correspondence to: *To whom correspondence should be addressed.
TEL: 91 22 42332030 (0), FAX: 91 22 26185422
There is a strong association between depression and memory impairment. The present study aims to assess the nootropic activity of duloxetine and piracetam combination. Male Swiss Albino mice were divided randomly into 4 groups. Treatment of normal saline (10 ml/kg), duloxetine (10 mg/kg), piracetam (100 mg/kg), and duloxetine (5 mg/kg) plus piracetam (50 mg/kg) were given through intra-peritoneal route to group I-IV, respectively. Transfer latency in elevated plus maze (EPM) and time spent in target quadrant in Morris water maze (MWM) were recorded. Estimation of brain monoamines in hippocampus, cerebral cortex, and whole brain were done using HPLC with fluorescence detector. Piracetam treated group showed significant decrease in transfer latency in EPM and increase in time spent in target quadrant recorded in MWM. Combination treated group failed to produce statistically significant nootropic effect in both EPM and MWM. Combination treated group failed to increase brain monoamine levels when compared against duloxetine and piracetam treated groups, separately. But there was exception of significant increase in norepinephrine levels in hippocampi when compared against duloxetine treated group. Results indicate no cognitive benefits with piracetam plus duloxetine combination. These findings can be further probed with the aim of understanding the interaction between duloxetine and piracetam as a future endeavor.
Keywords: nootropic activity, duloxetine, piraceta